Our Calling/Mission…

To detect diseases early in at least 100 Million people by 2030…

Our Story

We started CognitiveCare with a simple mission: to detect diseases early.

We work at the intersection of medicine, genetics and advanced computational sciences. We build models using AI and machine learning to acquire deep, comprehensive and precise insights about disease evolution and disease networks. Such insights can transform the way healthcare is practiced. Payers can identify opportunities for early intervention; providers can detect possible risks and blind-spots and life sciences companies can identify cases with high propensity of adverse events and progression-free survival.

We partner with some of the finest academic and research institutions globally to define some of the most pressing issues, identify sources of data and build suites of models to help generate the insights and bring them into action.

We focus on accelerating this journey of building, adopting and operationalizing these models – in some cases delivering models in weeks! What differentiates us from many is our focus on multi-dimensional medical research leveraging computational sciences, AI and machine learning.

About Us

We are a passionate bunch of problem solvers trying to solve some of the biggest and the most complex problems of healthcare. We feel, diseases don’t occur in isolation… they offer signals long before the symptoms become evident. Our focus is to dig deeper to understand the diseases and their evolution. Such granular insights will help us to understand the evolution of diseases, how they are inter-connected and the unique behavior of genes that can explain unique genetic pre-dispositions towards therapies and drugs.

Prior to CognitiveCare, many of us did seminal work in applying AI and machine learning not only in healthcare but also in money laundering, tax evasion, anti-terrorism and surveillance, banking and insurance.

We use advanced computational sciences, namely AI and deep learning to analyze massive volumes of data (of all kinds – medical records, notes, conversations, images, genetics, claims, surveys, drug research, drug usage etc.) to derive insights that can empower the doctors, payers, drug makers and public health professionals to intervene and manage the lives of citizens more effectively.

We go to market with the disease detection and networked models, organized both by diseases and by organs, with the artifacts to deliver insights seamlessly across all touch-points. Our customers can deploy these models within weeks.

We are headquartered in the Bay Area with a global foot-print of research and engineering centers.